From developing research programs to weighing in on legislative processes, CIMT is a community effort to facilitate and foster the research and clinical translation of cancer immunotherapies. In previous years, CIMT hosted two working groups that addressed immunoguiding standards (CIMT Immunoguiding Program-CIP) and the regulatory environment of new immunotherapies (CIMT Regulatory Research Group-RRG).

CIMT also supported the reporting framework MIATA (Minimal Information About T cell Assays) that enables an objective and thorough interpretation of published results from T-cell assays. See http://miataproject.org/ to learn more.